Moleculin Biotech (MBRX) Invested Capital (2016 - 2025)
Moleculin Biotech's Invested Capital history spans 10 years, with the latest figure at $15.0 million for Q4 2025.
- Quarterly results put Invested Capital at $15.0 million for Q4 2025, up 33.89% from a year ago — trailing twelve months through Dec 2025 was $15.0 million (up 33.89% YoY), and the annual figure for FY2025 was $15.0 million, up 33.89%.
- Invested Capital for Q4 2025 was $15.0 million at Moleculin Biotech, up from -$26.9 million in the prior quarter.
- In the past five years, Invested Capital ranged from a high of $88.6 million in Q1 2021 to a low of -$26.9 million in Q3 2025.
- The 5-year median for Invested Capital is $37.7 million (2023), against an average of $40.4 million.
- The sharpest move saw Invested Capital soared 479.46% in 2021, then tumbled 254.61% in 2025.
- Year by year, Invested Capital stood at $79.1 million in 2021, then crashed by 33.91% to $52.3 million in 2022, then crashed by 40.84% to $30.9 million in 2023, then tumbled by 63.76% to $11.2 million in 2024, then soared by 33.89% to $15.0 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods came in at $15.0 million, -$26.9 million, and -$3.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.